Clinical and prognostic association of total atrial conduction time in patients with heart failure: a report from Studies Investigating Co-morbidities Aggravating Heart Failure.


Journal

Journal of cardiovascular medicine (Hagerstown, Md.)
ISSN: 1558-2035
Titre abrégé: J Cardiovasc Med (Hagerstown)
Pays: United States
ID NLM: 101259752

Informations de publication

Date de publication:
Jul 2019
Historique:
pubmed: 16 4 2019
medline: 20 12 2019
entrez: 16 4 2019
Statut: ppublish

Résumé

The total atrial conduction time can be measured as the time from the onset of the P wave on the ECG to the peak of the A wave recorded at the mitral annulus using tissue Doppler imaging (A'; P-A'TDI); when prolonged, it might predict incident atrial fibrillation. We measured P-A'TDI in outpatients with heart failure and sinus rhythm enrolled in the SICA-HF programme. P-A'TDI measured at the lateral mitral annulus was longer in patients with HF with reduced [LVEF<50%, N = 141; 126 (112-146) ms; P = 0.005] or preserved left ventricular ejection fraction [LVEF>50% and NT-proBNP > 125 ng/l, N = 71; 128 (108-145) ms; P = 0.026] compared to controls [N = 117; 120 (106-135) ms]. Increasing age, left atrial volume and PR interval were independently associated with prolonged P-A'TDI. During a median follow-up of 1251 (956-1602) days, 73 patients with heart failure died (N = 42) or developed atrial fibrillation (N = 31). In univariable analysis, P-A'TDI was associated with an increased risk of the composite outcome of death or atrial fibrillation, but only increasing log [NT-proBNP], age and more severe symptoms (NYHA III vs. I/II) were independently related to this outcome. Patients in whom both P-A'TDI and left atrial volume were above the median (127 ms and 64 ml, respectively) had the highest incidence of atrial fibrillation (hazard ratio 6.61, 95% CI 2.27-19.31; P < 0.001 compared with those with both P-A'TDI and LA volume below the median). Measuring P-A'TDI interval identifies patients with chronic heart failure at higher risk of dying or developing atrial fibrillation during follow-up.

Sections du résumé

BACKGROUND BACKGROUND
The total atrial conduction time can be measured as the time from the onset of the P wave on the ECG to the peak of the A wave recorded at the mitral annulus using tissue Doppler imaging (A'; P-A'TDI); when prolonged, it might predict incident atrial fibrillation.
METHODS METHODS
We measured P-A'TDI in outpatients with heart failure and sinus rhythm enrolled in the SICA-HF programme.
RESULTS RESULTS
P-A'TDI measured at the lateral mitral annulus was longer in patients with HF with reduced [LVEF<50%, N = 141; 126 (112-146) ms; P = 0.005] or preserved left ventricular ejection fraction [LVEF>50% and NT-proBNP > 125 ng/l, N = 71; 128 (108-145) ms; P = 0.026] compared to controls [N = 117; 120 (106-135) ms]. Increasing age, left atrial volume and PR interval were independently associated with prolonged P-A'TDI. During a median follow-up of 1251 (956-1602) days, 73 patients with heart failure died (N = 42) or developed atrial fibrillation (N = 31). In univariable analysis, P-A'TDI was associated with an increased risk of the composite outcome of death or atrial fibrillation, but only increasing log [NT-proBNP], age and more severe symptoms (NYHA III vs. I/II) were independently related to this outcome. Patients in whom both P-A'TDI and left atrial volume were above the median (127 ms and 64 ml, respectively) had the highest incidence of atrial fibrillation (hazard ratio 6.61, 95% CI 2.27-19.31; P < 0.001 compared with those with both P-A'TDI and LA volume below the median).
CONCLUSION CONCLUSIONS
Measuring P-A'TDI interval identifies patients with chronic heart failure at higher risk of dying or developing atrial fibrillation during follow-up.

Identifiants

pubmed: 30985354
doi: 10.2459/JCM.0000000000000802
doi:

Types de publication

Journal Article Multicenter Study Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

442-449

Auteurs

Vincenzo Nuzzi (V)

Department of Cardiology, Hull York Medical School, University of Hull, Castle Hill Hospital, Cottingham, Kingston upon Hull, UK.
Dipartimento di scienze cardiovascolari, respiratorie, nefrologiche, anestesiologiche e geriatriche, Sapienza University, Rome, Italy.

Pierpaolo Pellicori (P)

Department of Cardiology, Hull York Medical School, University of Hull, Castle Hill Hospital, Cottingham, Kingston upon Hull, UK.
Robertson Institute of Biostatistics and Clinical Trials Unit, University of Glasgow, Glasgow.

Theodora Nikolaidou (T)

Department of Cardiology, Hull York Medical School, University of Hull, Castle Hill Hospital, Cottingham, Kingston upon Hull, UK.

Anna Kallvikbacka-Bennett (A)

Department of Cardiology, Hull York Medical School, University of Hull, Castle Hill Hospital, Cottingham, Kingston upon Hull, UK.

Concetta Torromeo (C)

Dipartimento di scienze cardiovascolari, respiratorie, nefrologiche, anestesiologiche e geriatriche, Sapienza University, Rome, Italy.

Francesco Barilla' (F)

Dipartimento di scienze cardiovascolari, respiratorie, nefrologiche, anestesiologiche e geriatriche, Sapienza University, Rome, Italy.

Damien Salekin (D)

Department of Cardiology, Hull York Medical School, University of Hull, Castle Hill Hospital, Cottingham, Kingston upon Hull, UK.

Kuldeep Kaur (K)

Department of Cardiology, Hull York Medical School, University of Hull, Castle Hill Hospital, Cottingham, Kingston upon Hull, UK.

Luca Monzo (L)

Dipartimento di scienze cardiovascolari, respiratorie, nefrologiche, anestesiologiche e geriatriche, Sapienza University, Rome, Italy.

John G F Cleland (JGF)

Robertson Institute of Biostatistics and Clinical Trials Unit, University of Glasgow, Glasgow.
National Heart & Lung Institute and National Institute of Health Research Cardiovascular Biomedical Research Unit, Royal Brompton & Harefield Hospitals, Imperial College, London, UK.

Andrew L Clark (AL)

Department of Cardiology, Hull York Medical School, University of Hull, Castle Hill Hospital, Cottingham, Kingston upon Hull, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH